The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Cell Plasticity and Heterogeneity in Cancer
Open accessAbstract
BACKGROUND: Heterogeneity within a given cancer arises from diverse cell types recruited to the tumor and from genetic and/or epigenetic differences amongst the cancer cells themselves. These factors conspire to create a disease with various phenotypes. There are 2 established models of cancer development and progression to metastatic disease. These are the clonal evolution and cancer stem cell models. CONTENT: The clonal evolution theory suggests that successive mutations accumulating in a given cell generate clonal outgrowths that thrive in response to microenvironmental selection pressures, dictating the phenotype of the tumor. The alternative cancer stem cell (CSC) model suggests that cancer cells with similar genetic BACKGROUNDs can be hierarchically organized according to their tumorigenic potential. Accordingly, CSCs reside at the apex of the hierarchy and are thought to possess the majority of a cancer's tumor-initiating and metastatic ability. A defining feature of this model is its apparent unidirectional nature, whereby CSCs undergo symmetric division to replenish the CSC pool and irreversible asymmetric division to generate daughter cells (non-CSCs) with low tumorigenic potential. However, evolving evidence supports a new model of tumorigenicity, in which considerable plasticity exists between the non-CSC and CSC compartments, such that non-CSCs can reacquire a CSC phenotype. These findings suggest that some tumors may adhere to a plastic CSC model, in which bidirectional conversions are common and essential components of tumorigenicity. SUMMARY: Accumulating evidence surrounding the plasticity of cancer cells, in particular, suggests that aggressive CSCs can be created de novo within a tumor. Given the current focus on therapeutic targeting of CSCs, we discuss the implications of non-CSC-to-CSC conversions on the development of future therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Self-citationMolecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Self-citationNowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
A Perspective on Cancer Cell Metastasis
Chaffer, C. L., & Weinberg, R. A. (2011) · Science · doi:10.1126/science.1203543 · Cited by 4,807
Self-citation
Cited by
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539
Self-citationEpithelial Plasticity: A Common Theme in Embryonic and Cancer Cells
Nieto, M. A. (2013) · Science · doi:10.1126/science.1234850 · Cited by 967
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Easwaran, H., Tsai, H.-C., & Baylin, S. B. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.015 · Cited by 915
“(Chaffer et al., 2011; Marjanovic et al., 2013) How do epigenetic properties specifically enter the picture for”
BackgroundInfluentialPhenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance
Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C., & Kuperwasser, C. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.011 · Cited by 598
Park, J., Choi, Y., Chang, H., Um, W., Ryu, J. H., & Kwon, I. C. (2019) · Theranostics · doi:10.7150/thno.37198 · Cited by 382
Gonzalez-Avila, G., Sommer, B., Mendoza-Posada, D. A., Ramos, C., Garcia-Hernandez, A. A., & Falfan-Valencia, R. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.010 · Cited by 373
de Sousa, V. M. L., & Carvalho, L. (2018) · Pathobiology · doi:10.1159/000487440 · Cited by 364
Heterogeneity of liver cancer and personalized therapy
Li, L., & Wang, H. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.07.018 · Cited by 339
Cancer stem cells, cancer cell plasticity and radiation therapy
Vlashi, E., & Pajonk, F. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.07.001 · Cited by 327
Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment
Sun, X.-X., & Yu, Q. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.92 · Cited by 318
Bhat, G. R., Sethi, I., Sadida, H. Q., Rah, B., Mir, R., Algehainy, N., Albalawi, I. A., Masoodi, T., Subbaraj, G. K., Jamal, F., et al. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10172-z · Cited by 281
Abseq: Ultrahigh-throughput single cell protein profiling with droplet microfluidic barcoding
Shahi, P., Kim, S. C., Haliburton, J. R., Gartner, Z. J., & Abate, A. R. (2017) · Scientific Reports · doi:10.1038/srep44447 · Cited by 259
Napabucasin: an update on the first-in-class cancer stemness inhibitor
Hubbard, J. M., & Grothey, A. (2017) · Drugs · doi:10.1007/s40265-017-0759-4 · Cited by 157
3D Bioprinting of Tumor Models for Cancer Research
Kang, Y., Datta, P., Shanmughapriya, S., & Ozbolat, I. T. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00791 · Cited by 112
Modeling of cancer metastasis and drug resistance via biomimetic nano-cilia and microfluidics
Kuo, C.-T., Chiang, C.-L., Chang, C.-H., Liu, H.-K., Huang, G.-S., Huang, R. Y.-J., Lee, H., Huang, C.-S., & Wo, A. M. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.008 · Cited by 65
Wang, J.-Z., Zhu, Y.-X., Ma, H.-C., Chen, S.-N., Chao, J.-Y., Ruan, W.-D., Wang, D., Du, F.-G., & Meng, Y.-Z. (2016) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.01.045 · Cited by 49
La Porta, C. A. M., & Zapperi, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.07.003 · Cited by 27
Kuo, C.-T., Liu, H.-K., Huang, G.-S., Chang, C.-H., Chen, C.-L., Chen, K.-C., Yun-Ju Huang, R., Lin, C.-H., Lee, H., Huang, C.-S., et al. (2014) · The Analyst · doi:10.1039/c4an00936c · Cited by 20
Boussommier-Calleja, A. (2020) · Bioengineering Innovative Solutions for Cancer · doi:10.1016/b978-0-12-813886-1.00013-9 · Cited by 10
Metadata
- Authors
- Marjanovic, N. D., Weinberg, R. A., & Chaffer, C. L.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-01-01
- Volume
- 59
- Issue
- 1
- Pages
- 168-179
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2130552015
- Cited by
- 400
- References
- 61
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.